News Releases

Text size
view with small font size
view with medium font size
view with large font size

Kyowa Hakko Kirin California, Inc. Announces Name Change to Kyowa Kirin Pharmaceutical Research, Inc. (225KB/1 page)

La Jolla, CA, March 15, 2016 – Kyowa Hakko Kirin California, Inc. (President: Yasunori Yamaguchi, Ph.D.; headquartered in La Jolla, California, "KKC"), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (President & CEO: Nobuo Hanai, Ph.D.; headquartered in Tokyo, Japan: "Kyowa Hakko Kirin") today announced its name change to Kyowa Kirin Pharmaceutical Research, Inc., following the decision of Kyowa Hakko Kirin to use "Kyowa Kirin" as a common company brand name. The change will be effective on April 1, 2016.

Kyowa Hakko Kirin California, Inc. Announces Closure of Clinical Assay Division (28KB/1 page)

La Jolla, CA, December 18, 2015 – Kyowa Hakko Kirin California, Inc., Inc. (President: Yasunori Yamaguchi, Ph.D.; headquartered in La Jolla, California, "KKR"), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151: President and CEO: Nobuo Hanai, Ph.D., "KHK"), today announced the closure of its Clinical Assay Division as part of the company's plan to focus on early stage drug discovery.

Kyowa Hakko Kirin California, Inc. Announces Appointment of Andrew McKnight, Ph.D. as Chief Scientific Officer (90KB/1 page)

La Jolla, CA, May 18, 2015 – Kyowa Hakko Kirin California, Inc., Inc. (President: Yasunori Yamaguchi, Ph.D.; headquartered in La Jolla, California, "KKR"), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151: President and CEO: Nobuo Hanai, Ph.D.), announced today the appointment of Andrew McKnight, Ph.D. as Chief Scientific Officer (CSO), effective May 18, 2015. Dr. McKnight brings to KKR extensive experience in the design and development of novel therapeutics in the therapeutic areas of Inflammation, Autoimmunity, and Allergy. In his new role as CSO, Dr. McKnight will be heading KKR's Research Division.

Transfer of BioWa's "External Innovation Engine" In-Licensing Activities to Kyowa Hakko Kirin California, Inc. – February 16, 2015 (150KB/1 page)

Kyowa Hakko Kirin California, Inc., Inc. (President: Yasunori Yamaguchi, Ph.D.; headquartered in La Jolla, California, "KKR"), a wholly owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (President & CEO: Nobuo Hanai, Ph.D.; headquartered in Tokyo, Japan: "Kyowa Hakko Kirin"), announced today the transfer of in‐licensing activities of its sister company, BioWa, Inc. (President and CEO: Yasunori Yamaguchi, Ph.D. headquartered in La Jolla, California; "BioWa"), which is also a wholly owned subsidiary of Kyowa Hakko Kirin, to KKR.

Kyowa Hakko Kirin California, Inc. Appoints New President– March 24, 2014

Kyowa Hakko Kirin California, Inc. is pleased to announce the appointment of Dr. Yasunori Yamaguchi to lead the company as its new President, effective March 24, 2014. Dr. Yamaguchi is also President and CEO of BioWa, Inc. (www.kyowa-kirin.com/biowa) and brings more than 20 years of research and business experience.

Kyowa Hakko Kirin California, Inc. Announces the Launch of its Newly Redesigned Website – August 27, 2013

On August 27th, Kyowa Hakko Kirin California, Inc., Inc. unveiled its new website which features a modern, streamlined look and enhanced navigation. The redesign of our website follows the launch of the global website (http://www.kyowa-kirin.com) of the Kyowa Hakko Kirin group in October 2012. Users are offered new content and the latest information about Kyowa Hakko Kirin California, Inc.'s research and business operations. The new website aims to emphasize Kyowa Hakko Kirin California, Inc.'s commitment to improving human health and attract people from around the world to discover who we are.

La Jolla Institute Continues Longtime Collaboration with Kyowa Hakko Kirin
California – July 30, 2013
(275KB/3 pages)

On July 30th, La Jolla Institute for Allergy and Immunology and Kyowa Hakko Kirin California, Inc., Inc. (KKR), a wholly-owned subsidiary of Kyowa Hakko Kirin Co., Ltd. (KHK), a global specialty pharmaceutical company, announced the signing of a new agreement that marks another milestone in one of the most enduring industry-academic collaborations in the world.

Kyowa Hakko Kirin California, Inc. and La Jolla Institute Celebrate 5th Anniversary in UC San Diego's Science Research Park – July 1, 2011

On July 1st, Kyowa Hakko Kirin California, Inc., Inc. and La Jolla Institute celebrated their 5th year at UCSD's Science Research Park. The move to the state-of-art facility in 2006 marked a major milestone in the longtime collaboration by further expanding research efforts on infectious diseases and immune system disorders and facilitating the translation of novel discoveries to therapeutic treatments.

Sanofi-Aventis and Kyowa Hakko Kirin Enter into a Collaboration and Licensing Agreement on an Anti LIGHT Fully Human Monoclonal Antibody – May 14, 2009 (90KB/2 pages)

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) announced today that they have signed a collaboration and licensing agreement under which sanofi-aventis receives worldwide rights to Kyowa Hakko Kirin's anti-LIGHT fully human monoclonal antibody.

Get Adobe® Reader®You need Adobe® Reader® to view these documents.
Download Adobe® Reader® of Adobe Systems here.

To Page Top